Navigation Links
Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
Date:12/6/2011

SAN DIEGO, December 6, 2011 /PRNewswire/ --

Speaking today at the plenary session of the IBC's International Antibody Conference in San Diego, Dr. Klaus Schwamborn, CDO of Pepscan Therapeutics, presented Pepscan's protein mimicry platform for the discovery of therapeutic antibodies.

In his presentation 'CLIPS meets GPCRs' Dr. Schwamborn introduced the CLIPS technology and the most recent developments of immunogen design. He showed data demonstrating that Pepscan's synthetic immunogens induce potent antibodies against GPCRs and therefore are able to mimic the native receptor. Resulting antibodies do not only bind strongly to the native receptor, but also show functionality with neutralizing activity in different cell based assays. Pepscan's approach was applied to different targets, supporting the concept of a generic platform for antibody generation for any given GPCR.

Monoclonal antibody therapy is very successful and has major advantages compared to small molecule therapy. However, it is very difficult to generate monoclonal antibodies for certain important drug targets, due to technical constraints, and so far no generic approach has been documented. This is in particular valid for G-protein coupled receptors (GPCR's), for which no FDA approved antibody exists. Over the last years, Pepscan Therapeutics has validated and optimized its CLIPS technology which enables the design and synthesis of conformationally stabilized peptides with a well-defined 3D-structure, resembling the native functional protein surface. New immunogen design strategies were established which allow grafting extracellular domains of any given GPCR onto a synthetic template, mimicking the native receptor structure in an optimal way.

The platform provides a systematic and efficient way of making synthetic immunogens which induce antibodies against the native target. With these immunogens, monoclonal antibodies can be generated by using common antibody technologies, like phage display libraries or hybridoma generation procedures.

Dr. Schwamborn stated: "Our approach has proven to be successful and the fact that we have the possibility to tailor antibodies to certain GPCR domains enables us to engineer antibodies which fulfill certain biological requirements. The immunogen design concept for mimicking extracellular domains of discontinuous epitopes might be also applicable to other important target classes like ion channels".

About Pepscan Therapeutics

Pepscan Therapeutics is a privately held company based in Lelystad, The Netherlands. Pepscan is using its proprietary high throughput CLIPS protein mimicking technology for the development of novel constrained therapeutic peptides and immunogens. Besides its pipeline of proprietary anti-GPCR monoclonal antibody products, Pepscan has various ongoing collaborations with leading pharmaceutical and biotech companies to develop novel therapeutics based on the proprietary CLIPS technology.

About CLIPS

CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of structurally complex protein domains. CLIPS therapeutic peptides have been shown to exert improved activity and stability. CLIPS peptides are also used as superior immunogens for antibody generation against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins, such as GPCRs.

http://www.pepscan.com 


'/>"/>
SOURCE Pepscan Therapeutics BV
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pepscan Therapeutics Strengthens Management Team
2. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
3. Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing
4. FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics Resubmitted Pixantrone New Drug Application
5. GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
6. Novelos Therapeutics Prices $5.9 Million Public Offering
7. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
8. Antiviral Therapeutics - Technologies, Markets and Companies
9. Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
10. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
11. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):